SMT202000056T1 - Co-somministrazione di un agente legato ad un peptide di internalizzazione tat con un inibitore di degranulazione dei mastociti - Google Patents

Co-somministrazione di un agente legato ad un peptide di internalizzazione tat con un inibitore di degranulazione dei mastociti

Info

Publication number
SMT202000056T1
SMT202000056T1 SM20200056T SMT202000056T SMT202000056T1 SM T202000056 T1 SMT202000056 T1 SM T202000056T1 SM 20200056 T SM20200056 T SM 20200056T SM T202000056 T SMT202000056 T SM T202000056T SM T202000056 T1 SMT202000056 T1 SM T202000056T1
Authority
SM
San Marino
Prior art keywords
tat
administration
mast cell
cell degranulation
agent linked
Prior art date
Application number
SM20200056T
Other languages
English (en)
Italian (it)
Inventor
Michael Tymianski
Jonathan David Garman
Hong Cui
Original Assignee
Nono Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nono Inc filed Critical Nono Inc
Publication of SMT202000056T1 publication Critical patent/SMT202000056T1/it

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/275Nitriles; Isonitriles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/275Nitriles; Isonitriles
    • A61K31/277Nitriles; Isonitriles having a ring, e.g. verapamil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10Peptides having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036Retroviridae, e.g. leukemia viruses
    • C07K16/1045Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1072Regulatory proteins, e.g. tat, rev, vpt
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
SM20200056T 2009-06-10 2010-06-10 Co-somministrazione di un agente legato ad un peptide di internalizzazione tat con un inibitore di degranulazione dei mastociti SMT202000056T1 (it)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18594309P 2009-06-10 2009-06-10
EP10786870.5A EP2440231B1 (en) 2009-06-10 2010-06-10 Co-administration of an agent linked to a tat-internalization peptide with a mast cell degranulation inhibitor
PCT/US2010/038226 WO2010144742A2 (en) 2009-06-10 2010-06-10 Co-administration of an agent linked to an internalization peptide with an anti-inflammatory

Publications (1)

Publication Number Publication Date
SMT202000056T1 true SMT202000056T1 (it) 2020-03-13

Family

ID=43309471

Family Applications (1)

Application Number Title Priority Date Filing Date
SM20200056T SMT202000056T1 (it) 2009-06-10 2010-06-10 Co-somministrazione di un agente legato ad un peptide di internalizzazione tat con un inibitore di degranulazione dei mastociti

Country Status (16)

Country Link
US (4) US8933013B2 (enExample)
EP (2) EP2440231B1 (enExample)
JP (5) JP5886192B2 (enExample)
AU (1) AU2010259986B2 (enExample)
CA (2) CA3018494C (enExample)
CY (1) CY1122584T1 (enExample)
DK (1) DK2440231T3 (enExample)
ES (1) ES2765281T3 (enExample)
HR (1) HRP20192230T1 (enExample)
HU (1) HUE046640T2 (enExample)
LT (1) LT2440231T (enExample)
PL (1) PL2440231T3 (enExample)
PT (1) PT2440231T (enExample)
SI (1) SI2440231T1 (enExample)
SM (1) SMT202000056T1 (enExample)
WO (1) WO2010144742A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8080518B2 (en) 2007-12-05 2011-12-20 Arbor Vita Corporation Co-administration of an agent linked to an internalization peptide with an anti-inflammatory
PL2320927T3 (pl) * 2008-07-09 2016-02-29 Univ Copenhagen Modyfikowane peptydy jako potencjalne inhibitory w reakcjach receptorów PSD 95 i NMD
AU2010259986B2 (en) 2009-06-10 2015-04-02 Nono Inc. Co-administration of an agent linked to an internalization peptide with an anti-inflammatory
HRP20171564T1 (hr) 2009-09-22 2017-11-17 Medicago Inc. Postupak za pripremu biljnih čestica sličnih virusu (vlp)
TWI620816B (zh) 2011-03-23 2018-04-11 苜蓿股份有限公司 植物衍生蛋白回收方法
KR102022116B1 (ko) 2011-06-24 2019-09-18 노노 인코포레이티드 허혈에 대한 psd-95 억제제와의 조합 요법
US10251935B2 (en) 2012-11-28 2019-04-09 Nono Inc. Lyophilized formulation comprising tat-NR2B9C, histidine and trehalose
HUE043820T2 (hu) * 2012-11-28 2019-09-30 Nono Inc Liofilizált TAT-NR2B9c készítmény
WO2016172219A1 (en) * 2015-04-24 2016-10-27 The Arizona Board Of Regents On Behalf Of The University Of Arizona Methods and compositions for inhibition of toll-like receptors (tlrs)-mediated inflammation
US10808253B2 (en) 2015-12-28 2020-10-20 Idemitsu Kosan Co., Ltd. Peptide tag and tagged protein including same
EA039314B1 (ru) * 2017-07-05 2022-01-12 Биоселз (Бейдзин) Биотек Ко., Лтд. Фармацевтически приемлемые соли полипептидов и их применение
CA3079081A1 (en) 2017-10-19 2019-04-25 Michael D. Bartberger Benzimidazole derivatives and their uses
CN115279797A (zh) * 2020-01-09 2022-11-01 诺诺公司 用于治疗中风和相关疾病的抗纤溶酶肽
EP4274596A4 (en) 2021-01-08 2024-12-25 NoNO Inc. Plasmin-resistant peptides for improved therapeutic index

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5804604A (en) 1989-12-21 1998-09-08 Biogen, Inc. Tat-derived transport polypeptides and fusion proteins
US6316003B1 (en) 1989-12-21 2001-11-13 Whitehead Institute For Biomedical Research Tat-derived transport polypeptides
US5331573A (en) 1990-12-14 1994-07-19 Balaji Vitukudi N Method of design of compounds that mimic conformational features of selected peptides
EP1159418A2 (en) 1998-12-11 2001-12-05 Biomira Inc. Muc-1 antagonists and methods of treating immune disorders
US20040226056A1 (en) 1998-12-22 2004-11-11 Myriad Genetics, Incorporated Compositions and methods for treating neurological disorders and diseases
US20060148711A1 (en) 1999-05-14 2006-07-06 Arbor Vita Corporation Molecular interactions in neurons
US7510824B2 (en) * 1999-06-02 2009-03-31 Nono Inc. Method of screening peptides useful in treating traumatic injury to the brain or spinal cord
US7595297B2 (en) 1999-06-02 2009-09-29 Michael Tymianski Method of reducing injury to mammalian cells
DE60026313D1 (de) 1999-07-23 2006-04-27 Uutech Ltd Sensibilisierung von roten blutkörperchen gegenüber ultraschall durch einwirkung eines elektrischen feldes
MXPA02001857A (es) 1999-08-24 2003-07-14 Cellgate Inc Composiciones y metodos para incrementar la entrega de drogas a traves y dentro de tejidos epiteliales.
US6204245B1 (en) 1999-09-17 2001-03-20 The Regents Of The University Of California Treatment of narcolepsy with immunosuppressants
US6864355B1 (en) 2000-05-02 2005-03-08 Yale University Inhibition of NF-κB activation by blockade of IKKβ-NEMO interactions at the NEMO binding domain
US20020032154A1 (en) 2000-06-07 2002-03-14 Peyman John A. Interferon-suppressing placental lactogen peptides
AU2002356511A1 (en) 2001-07-30 2003-04-01 Immunex Corporation T. reesei phytase enyzmes, polynucleides encoding the enzymes, vectors and host cells thereof, and methods of using
WO2004045535A2 (en) * 2002-11-14 2004-06-03 Arbor Vita Corporation Molecular interactions in neurons
US20060276455A1 (en) 2003-02-13 2006-12-07 Lindsberg Perttu J Use of a mast cell activation or degranulation blocking agent in the manufacture of a medicament for the treatment of cerebral ischemia
WO2005037317A2 (en) * 2003-10-17 2005-04-28 Cornell Research Foundation, Inc. Mast cell-derived renin
US20050256065A1 (en) * 2004-01-26 2005-11-17 Permasight Method for stabilizing changes in corneal curvature in an eye by administering compositions containing stabilizing ophthalmic agents
US7151084B2 (en) 2004-12-27 2006-12-19 Miller Landon C G Compound and method of treating neurogenic conditions using non-steroidal anti-inflammatory drug complexes
KR101384572B1 (ko) 2005-12-30 2014-04-24 아버 비타 코포레이션 Pdz 상호작용의 소형 분자 억제제
ES2804424T3 (es) * 2006-07-11 2021-02-08 Nono Inc Péptido y composición del mismo para usar en el tratamiento del accidente cerebrovascular con fiebre
EP1884521A1 (en) * 2006-07-31 2008-02-06 Xigen S.A. Fusion peptide for inhibiting interaction of neuronal NMDA receptor (NMDAR) and NMDAR interacting proteins
EP2120987B1 (en) * 2007-03-02 2014-01-15 NoNO Inc. Treating stroke and other diseases without inhibiting n-type calcium channels
WO2009006611A1 (en) 2007-07-03 2009-01-08 Arbor Vita Corporation Small molecule inhibitors of pdz interactions
EP2178549B1 (en) 2007-07-26 2016-09-14 Revance Therapeutics, Inc. Antimicrobial peptide and compositions thereof
ES2328776B1 (es) 2007-11-19 2010-07-06 Proyecto De Biomedicina Cima S.L. Peptidos con capacidad para unirse a escurfina y aplicaciones.
US8080518B2 (en) 2007-12-05 2011-12-20 Arbor Vita Corporation Co-administration of an agent linked to an internalization peptide with an anti-inflammatory
PL2320927T3 (pl) 2008-07-09 2016-02-29 Univ Copenhagen Modyfikowane peptydy jako potencjalne inhibitory w reakcjach receptorów PSD 95 i NMD
AU2010259986B2 (en) 2009-06-10 2015-04-02 Nono Inc. Co-administration of an agent linked to an internalization peptide with an anti-inflammatory

Also Published As

Publication number Publication date
US20190038760A1 (en) 2019-02-07
HUE046640T2 (hu) 2020-03-30
JP2023017813A (ja) 2023-02-07
HRP20192230T1 (hr) 2020-03-20
JP2020125328A (ja) 2020-08-20
CY1122584T1 (el) 2021-01-27
US20170043030A1 (en) 2017-02-16
US20150126460A1 (en) 2015-05-07
JP6238934B2 (ja) 2017-11-29
WO2010144742A3 (en) 2011-04-21
PT2440231T (pt) 2020-01-08
JP2018030859A (ja) 2018-03-01
CA3018494A1 (en) 2010-12-16
EP2440231B1 (en) 2019-12-04
AU2010259986B2 (en) 2015-04-02
JP7209364B2 (ja) 2023-01-20
EP3682895A1 (en) 2020-07-22
PL2440231T3 (pl) 2020-05-18
CA2765171C (en) 2018-10-02
EP2440231A4 (en) 2013-04-24
JP2016000735A (ja) 2016-01-07
ES2765281T3 (es) 2020-06-08
US10046060B2 (en) 2018-08-14
US20120252731A1 (en) 2012-10-04
SI2440231T1 (sl) 2020-08-31
LT2440231T (lt) 2020-01-10
AU2010259986A1 (en) 2012-01-12
JP6775478B2 (ja) 2020-10-28
JP2012530060A (ja) 2012-11-29
WO2010144742A2 (en) 2010-12-16
US8933013B2 (en) 2015-01-13
CA3018494C (en) 2021-12-07
JP5886192B2 (ja) 2016-03-16
CA2765171A1 (en) 2010-12-16
EP2440231A2 (en) 2012-04-18
DK2440231T3 (da) 2020-01-13
US9433685B2 (en) 2016-09-06

Similar Documents

Publication Publication Date Title
SMT202000056T1 (it) Co-somministrazione di un agente legato ad un peptide di internalizzazione tat con un inibitore di degranulazione dei mastociti
ZA201209561B (en) Compositions and methods related to protein a (spa) variants
SG10201404280XA (en) Use of stem cells to reduce leukocyte extravasation
GB2476329B (en) Improved access to structures
SG10201913618WA (en) Use of stem cells to reduce leukocyte extravasation
PL2588420T3 (pl) Usuwanie kamienia szczawianowego kompozycjami kwasowymi
TWM388993U (en) Structure of screwdriver head
IL222506A (en) Tetrazine replacement
HU0900178D0 (en) Stronger paper-pallet with use of simple geometrical structure
TWM385439U (en) Angle positioning structure of rocker spanner
GB2478170B (en) Improvements relating to dc-dc coverters
TWM402371U (en) Discharge head structure of wall-embedding type
TWM372243U (en) Buckling structure of adaptor
TWM390844U (en) Structure improvement of a screwdriver
HU0900810D0 (en) Equipment to reduce gas consumption
GB201006692D0 (en) Structure of fuel economizer
TWM371801U (en) Structure of fastener
GB0906919D0 (en) Inhibitor complex structure
TWM402409U (en) Bolt-sound structure of performance gun
GB0918486D0 (en) Clever is
TWM402171U (en) Structure of F-handle wrench
GB201018482D0 (en) Crystal structure of isoglutaminyl cyclase
TWM390845U (en) Hand tool with luminous structure
GB201013843D0 (en) Crystal structure of glutaminyl cyclase
TWM387333U (en) Energy saving billboard structure